The result of an early-phase trial with crizotinib, an inhibitor developed for ALK and Met, has generated considerable interest as a therapeutic option in patients with NSCLC who harbor EML4-ALK mutations [43]; a number of clinical trials are currently underway to determine their efficacy and parameters for optimal use. The gene discussed is ALK; the disease is non-small cell lung carcinoma.